In the next five years, the world’s leading oncology centers will not only hire the best physicians but also equip them with cutting-edge AI copilots that optimize cancer diagnosis and treatment 🤖⚕️.
AIX Ventures is excited to lead the oversubscribed Series A for Ataraxis AI, which developed the world’s first AI-native oncology diagnostic for breast cancer 🚀.
Their breakthrough AI foundation model, Kestrel, identifies complex, previously invisible patterns linked directly to patient outcomes across all cancer types. Kestral empowers doctors with superior treatment recommendations to improve care for millions of cancer patients globally.
There’s no better team to tackle this massive opportunity than Jan Witowski MD PhD and Krzysztof Geras, and the team they’ve assembled 🙌.
We are also excited to have a world-class investor syndicate, including Floating Point, Thiel Capital, Bertelsmann Investments, Giant Ventures, and Obvious Ventures 🎉
Read more in TechCrunch: https://lnkd.in/gg45wkVu